The announcement of a licensing agreement is typically viewed positively by the market, as it can lead to new revenue streams and partnerships. For Solid Biosciences, this agreement with Armatus Bio for the use of AAV-SLB101 represents a significant development in their operations, likely contributing to the positive movement in their stock price. The relevance is high because the news directly involves SLDB, and the importance is also elevated due to the potential financial and strategic benefits of the agreement.